How to Recognize, Diagnose, and Treat Patients With BPDCN

home / case-based-roundtable-series / how-to-recognize-diagnose-and-treat-patients-with-bpdcn

This roundtable series discusses blastic plasmacytoid dendritic cell neoplasms in patients and the ways to identify and provide therapy for this rare disease, as discussed by key opinion leaders and participants at virtual live events.

Multi-Stage Trial of Tagraxofusp Shows Frontline Efficacy in BPDCN

Multi-Stage Trial of Tagraxofusp Shows Frontline Efficacy in BPDCN

Andrew A. Lane, MD, PhD
September 28th 2022

Andrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.

Update Shows Long-Term Benefits of Tagraxofusp in BPDCN

Update Shows Long-Term Benefits of Tagraxofusp in BPDCN

Naveen Pemmaraju, MD
October 10th 2022

Naveen Pemmaraju, MD discusses the long-term results of the STML-401-0114 trial that demonstrated the benefits of tagraxofusp-ezrs as a monotherapy for patients with blastic plasmacytoid dendritic cell neoplasms.

Exploring the Background and Clinical Presentation of BPDCN

Exploring the Background and Clinical Presentation of BPDCN

Targeted Oncology Staff
November 14th 2022

During a Targeted Oncology case-based roundtable event, Jeffrey E. Lancet, MD, discussed the clinical presentation of blastic plasmacytoid dendritic cell neoplasm and how it came to be recognized as a distinct rare hematologic malignancy. This is the first of 2 articles based on this event.

Lancet Reviews the Key Treatment Options for BPDCN

Lancet Reviews the Key Treatment Options for BPDCN

Targeted Oncology Staff
December 2nd 2022

During a Targeted Oncology case-based roundtable event, Jeffrey E. Lancet, MD, discussed the data behind tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm. This is the second of 2 articles based on this event.